A systematic review on dysconnectivity in face and emotion processing networks in schizophrenia.

Cogn Affect Behav NeurosciFeb 24, 2026 (epub)
Clinical ResearchPsychiatry

Amritha Harikumar, Junqiang Dai, Elaine F Walker et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined functional MRI studies of face and emotion processing networks in people with schizophrenia, including but not limited to first-episode psychosis. The authors searched four databases and reviewed nine English-language studies published from 2020 to 2025. Across resting-state and task-based studies, dysconnectivity was most consistently reported in executive-function, theory-of-mind/mentalizing, default-mode, limbic, and visual-perceptual systems. The review also described social-cognitive difficulties, particularly in processing negative emotional faces, and noted elevated PANSS positive scores alongside social-cognition deficits in first-episode patients.

Key findings

  • Nine studies published from 2020 to 2025 met the review criteria.
  • Dysconnectivity was most consistently reported in executive-function, theory-of-mind/mentalizing, default-mode, limbic, and visual-perceptual systems.
  • Reviewed studies linked social-cognition deficits with difficulty recognizing and processing negative emotional faces.
  • First-episode patients showed elevated PANSS positive scores alongside social-cognition deficits.

Why it matters

Face and emotion processing difficulties can affect social interaction and social cognition in schizophrenia. The review brings together evidence that these difficulties occur alongside altered connectivity across several brain systems, rather than a single network. This network-level perspective may help frame research into how clinical symptoms and social-cognitive impairments relate, while the small evidence base calls for caution.

What to keep in mind

Only nine studies met the review criteria, and the included studies varied in patient subtype and whether fMRI was resting-state or task-based.

Source

Published in Cogn Affect Behav Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.